TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Travere Therapeutics, Inc.

Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026

$50.49+0.89 (+1.79%)

Close on Oct 19, 2026

Market cap: $4.72B
P/E (TTM): –
Dividend yield: –

Travere Therapeutics, Inc. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2025-12-31	FY 2025 2024-12-31	FY 2024 2023-12-31	FY 2023 2022-12-31	FY 2022 2021-12-31	FY 2021 2020-12-31	FY 2020 2019-12-31	FY 2019 2018-12-31	FY 2018 2017-12-31	FY 2017 2016-12-31	FY 2016 2015-12-31	FY 2015 2014-12-31	FY 2014 2013-12-31	FY 2012 2012-02-29	FY 2011 2011-02-28
Revenue	491	233	145	109	132	198	175	164	155	134	100	28	0	0	0
Cost of Revenue	10	7.74	11	4.42	3.82	6.13	5.23	5.53	3.61	4.55	2.19	0.57	0	0.01	0.01
Gross Profit	480	225	134	105	128	192	170	159	151	129	98	28	0	-0.01	-0.01
Research & Development	206	217	245	227	201	132	141	124	78	71	50	48	7.08	–	–
Selling, General & Admin	337	264	266	198	126	136	129	104	101	92	80	60	18	–	–
General & Administrative	–	–	–	–	–	–	–	–	–	–	–	–	–	0.01	0.01
Advertising Expenses	15	7.80	0	–	–	–	–	–	–	–	–	–	–	–	–
Operating Expenses	–	–	–	–	–	–	–	244	209	192	151	108	25	–	–
Total Costs & Expenses	554	557	533	429	331	374	313	244	209	–	–	–	–	0.01	0.02
Operating Income	-63	-324	-388	-320	-199	-176	-137	-80	-54	-58	-51	-80	-25	–	–
Interest Expense	11	11	11	11	20	19	19	9.81	4.42	4.73	7.70	7.40	0	–	–
Interest & Investment Income	13	18	22	6.28	1.99	5.00	10	5.50	3.23	–	–	–	–	–	–
Other Non-Operating Income	14	3.32	12	-11	-17	-13	-9.09	-22	-4.57	0.63	156	-34	-9.78	–	–
Merger & Restructuring Charges	0	2.44	11	0	0	0	0	-0.24	3.61	0.89	0	–	–	–	–
Asset Impairment Charges	0	1.20	0	0	0	0	0	0	0	0	0	0	0	–	–
Gain (Loss) on Investments	–	–	–	–	–	–	–	–	–	–	–	2.35	0.37	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	-7.50	–	–	-0.06	0.90	0	–	–	–
Legal Settlements	–	–	–	–	–	–	0	0	-2.63	-5.21	16	0	0	–	–
Pretax Income	-49	-321	-376	-331	-217	-189	-146	-102	-58	-58	105	-113	-35	–	–
Income Tax Expense	0.99	0.12	0.22	0.31	0.41	-19	-0.02	0.81	1.37	-9.68	-12	-2.46	0.08	–	–
Income from Continuing Operations	-50	-321	-376	-331	-217	–	–	–	–	–	–	–	–	0.00	0.00
Income from Discontinued Operations	25	-0.92	265	53	37	–	–	–	–	–	–	–	–	–	–
Net Income	-26	-322	-111	-278	-180	-169	-146	-103	-60	-48	117	-111	-35	-0.01	-0.02
Net Income to Common	-26	-322	-111	-278	-180	-169	-146	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-0.29	-4.08	-1.50	-4.37	-3.01	-3.56	-3.46	-2.54	-1.54	-1.29	3.49	-4.43	-2.44	–	–
EPS (Diluted)(per share)	-0.29	-4.08	-1.50	-4.37	-3.01	-3.56	-3.46	-2.54	-1.54	-1.29	3.17	-4.43	-2.44	–	–
Shares Outstanding (Basic, Weighted)(shares)	89	79	74	64	60	48	42	40	39	37	34	25	14	0.11	0.11
Shares Outstanding (Diluted, Weighted)(shares)	89	79	74	64	60	48	42	40	39	38	38	25	14	0.11	0.11
EBITDA	-2.08	-280	-350	-299	-187	-152	-117	-61	-36	-42	-37	-74	-25	–	–
Net Interest Income	–	–	–	–	–	–	–	5.50	3.23	3.98	–	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 98.6%
Operating margin: -6.8%
Net margin: -7.4%
Return on equity, FY2026: -29.4%

Financial strength

Current ratio: 4.05
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 77.4%

Valuation

P/E ratio: –
Price to sales: 7.98
Price to book: 192.47
Dividend yield: –